Tech Transfer Roundup: UCSD Sees Many Benefits From Entrepreneurs In Residence Program
Asterias obtains IP estate related to ischemic stroke from University of California. Plus Apeiron, Qualigen, Biovaxys and AbbVie turn to academic partners for early-stage cancer assets.
You may also be interested in...
Executive Interview: Reducing “ER stress” is one of the potential mechanisms of action of a novel candidate Parkinson’s agent being evaluated by Finland’s Herantis, which completed an additional stock market listing, in Sweden, last month.
The New York biotech announces option deals with two universities, asset license from CBM BioPharma. Bayer inks research collaborations with Japan’s RiKen and with a pair of Boston research hospitals.
The first close of a series C financing should enable InRhythm to enter Phase III as an inhalable anti-arrhythmic for paroxysmal atrial fibrillation in a medically supervised setting.